MP16-13 PATIENT PERCEPTION OF TRANSURETHRAL RESECTION OF BLADDER TUMOR VS. CHEMOABLATION FOR NON-MUSCLE INVASIVE BLADDER CANCER TREATMENT

Abstract

You have accessJournal of UrologyBladder Cancer: Non-invasive II (MP16)1 Sep 2021MP16-13 PATIENT PERCEPTION OF TRANSURETHRAL RESECTION OF BLADDER TUMOR VS. CHEMOABLATION FOR NON-MUSCLE INVASIVE BLADDER CANCER TREATMENT Taylor Parisse, Katy Reines, Ramsandkar Basak, Dana Mueller, and Angela Smith Taylor ParisseTaylor Parisse More articles by this author , Katy ReinesKaty Reines More articles by this author , Ramsandkar BasakRamsandkar Basak More articles by this author , Dana MuellerDana Mueller More articles by this author , and Angela SmithAngela Smith More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002001.13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Patients with non-muscle invasive bladder cancer (NMIBC) often require invasive monitoring and treatment. As new treatments emerge, our objective was to evaluate patient treatment preference for repeat transurethral resections of bladder tumor (TURBT) versus chemoablation and examine associations between patient and disease characteristics with treatment preference. METHODS: Patients diagnosed with NMIBC who had undergone one or more TURBTs were recruited via the Bladder Cancer Advocacy Network (BCAN) Patient Survey Network (PSN) to complete a web-based survey. The survey ascertained patient demographics and clinical information. The survey also addressed treatment preference between two hypothetical options, surgical therapy (TURBT) versus intravesical chemoablation without surgery, and reasons for treatment preference. Bivariable and multivariable analyses were performed. RESULTS: A total of 350 patients responded to the survey among whom 60% preferred TURBT and 40% preferred intravesical chemoablation. Predictors of treatment preference for chemoablation included United States (U.S.) residence (p=0.02), more recent TURBT experience (p=0.03), high tumor grade (p=0.03), or expressed priority of recurrence risk (p <0.0001) (Figure). On multivariable analysis, patients were more likely to prefer chemoablation if a U.S. resident (OR=2.03; 95% CI 1.03, 4.00) or if they expressed priority of recurrence risk over effectiveness (OR=15.5; 95% CI 7.8, 30.5). CONCLUSIONS: When provided chemoablation as a hypothetical treatment option for bladder cancer recurrence, a significant proportion of patients preferred this non-surgical treatment to conventional TURBT, more commonly among U.S. patients. Patients who had a recent experience with TURBT as well as those who expressed recurrence risk as a priority in decision-making were also more likely to prefer chemoablation. Source of Funding: Funding provided by a Bladder Cancer Advocacy Network Patient Survey Network Award © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e301-e302 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Taylor Parisse More articles by this author Katy Reines More articles by this author Ramsandkar Basak More articles by this author Dana Mueller More articles by this author Angela Smith More articles by this author Expand All Advertisement Loading ...